The FDA has approved the first Lyme disease vaccine (LYMErix, SmithKline Biologicals, Philadelphia). The vaccine, recombinant OspA, is administered in three doses at 0, 1, and 12 months and is indicated for active immunization against Lyme disease in individuals 15 to 70 years of age. Individuals at greatest risk may be those who live or work in grassy or wooded areas that are infested with Borrelia burgdorferi–infected ticks and those who plan travel to or pursue recreational activities in such areas. FDA has emphasized that while the vaccine may provide protection for most people when all three doses are administered, it does not prevent all cases of Lyme disease. Therefore, patients receiving the vaccine should be told of the importance of completing the full vaccination sequence and continuing to take standard preventive measures against infection, including wearing protective clothing, using tick repellent, and removing attached ticks.
Nightingale SL. Lyme Disease Vaccine Approved. JAMA. 1999;281(5):408. doi:10.1001/jama.281.5.408
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: